Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier García Del Muro

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Anti-Cancer Drugs|June 29, 2012
Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinibRafael López López, Xavier García del Muro
Expert Opinion on Investigational Drugs|December 5, 2018
Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcomaJuan Martin-Liberal, Ezequiel Pérez, Xavier García Del Muro
Expert Review of Anticancer Therapy|January 15, 2015
Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?Juan Martin-Liberal, Oscar M Tirado, Xavier García del Muro
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 23, 2012
SEOM clinical guidelines for the management of adult soft tissue sarcomasXavier García del Muro Solans, Javier Martín Broto, Pilar Lianes Barragán, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 11, 2008
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinibLuis Paz-Ares, Xavier García del Muro, Enrique Grande, et al.
Cancers|March 28, 2026
<i>TFE3</i>-Rearranged and <i>TFEB</i>-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic AdvancesMikel Portu, Mario Balsa, Maria Cotaina, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 5, 2010
Molecular mechanisms behind the resistance of cisplatin in germ cell tumoursJosep Ma Piulats, Laura Jiménez, Xavier García del Muro, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 30, 2014
Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcomaMax Brosa, Xavier García del Muro, Jaume Mora, et al.
Sarcoma|June 16, 2012
Targeted therapies in sarcomas: challenging the challengeJuan Martín Liberal, Laura Lagares-Tena, Miguel Sáinz-Jaspeado, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2014
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)Andrés Poveda, Xavier García del Muro, Jose Antonio López-Guerrero, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Anti-Cancer Drugs|June 29, 2012
Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinibRafael López López, Xavier García del Muro
Expert Opinion on Investigational Drugs|December 5, 2018
Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcomaJuan Martin-Liberal, Ezequiel Pérez, Xavier García Del Muro
Expert Review of Anticancer Therapy|January 15, 2015
Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?Juan Martin-Liberal, Oscar M Tirado, Xavier García del Muro
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 23, 2012
SEOM clinical guidelines for the management of adult soft tissue sarcomasXavier García del Muro Solans, Javier Martín Broto, Pilar Lianes Barragán, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 11, 2008
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinibLuis Paz-Ares, Xavier García del Muro, Enrique Grande, et al.
Cancers|March 28, 2026
<i>TFE3</i>-Rearranged and <i>TFEB</i>-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic AdvancesMikel Portu, Mario Balsa, Maria Cotaina, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 5, 2010
Molecular mechanisms behind the resistance of cisplatin in germ cell tumoursJosep Ma Piulats, Laura Jiménez, Xavier García del Muro, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 30, 2014
Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcomaMax Brosa, Xavier García del Muro, Jaume Mora, et al.
Sarcoma|June 16, 2012
Targeted therapies in sarcomas: challenging the challengeJuan Martín Liberal, Laura Lagares-Tena, Miguel Sáinz-Jaspeado, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2014
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)Andrés Poveda, Xavier García del Muro, Jose Antonio López-Guerrero, et al.
Pageof 7